ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Editas and Allergan kick off first in vivo CRISPR gene-editing clinical trial

by Ryan Cross
August 2, 2019 | APPEARED IN VOLUME 97, ISSUE 31

 

Editas Medicine and Allergan are kicking off the first clinical trial of in vivo CRISPR gene editing, in which the editing of DNA takes place inside a person’s body. The trial will test CRISPR’s ability to remove a genetic mutation in people with a form of progressive childhood blindness. Genetic instructions for making the CRISPR-Cas9 machinery will be encoded into viruses, which will be injected under the retina. Another pair of companies—Crispr Therapeutics and Vertex Pharmaceuticals—have begun testing ex vivo CRISPR gene editing for inherited blood diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment